1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Sysmex Corporation

Sysmex Corporation

SSMXF
Sysmex CorporationUS flagOther OTC
8.85
USD
- -
- -
5.50BMarket Cap
Sysmex Corporation
SSMXF
(Other OTC)

Recent

price

8.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
378.25
202.46
218.55
235.64
297.41
355.95
405.36
400.37
451.16
468.96
482.19
486.78
579.94
654
737.02
815.72
398.3
Revenue per Share
31.79
18.53
19.47
22.93
33.16
42.83
63.03
65.1
62.76
65.87
55.7
50.91
70.29
72.94
79.27
86.07
43.95
Basic EPS, GAAP
48.2
16.8
13.98
22.65
31.38
35.62
31.63
21.99
42.48
25.19
42.65
49.59
42.57
41.95
21.9
61.4
8.41
Free Cash Flow per Basic Share
8.49
4.91
5.16
5.99
7.32
10.83
15.32
18.66
19.99
23.33
24
23.99
24.32
26.33
28.07
29
14.07
Dividend per Share
244.52
135.9
135.41
152.07
177.24
226.18
273.41
320.61
363.61
405.99
437.83
462.93
509.86
555.18
607.99
669.88
639.29
Book Value per Share
263.46
142.21
155.06
181.73
197.25
223.79
255.45
289.53
319.13
351.87
363.32
393.82
444.44
474.74
525.23
574.42
536.25
Tangible Book Value per Share
307
616
617
618
620
622
623
624
625
626
626
627
627
628
626
624
625
Basic Weighted Avg Shares
116,174
124,694
134,743
145,577
184,538
221,376
252,622
249,899
281,935
293,506
301,980
305,073
363,780
410,502
461,510
508,643
248,811
Sales/Revenue/Turnover
13.52
14.67
14.25
14.98
17.81
20.06
24.04
20.69
21.34
20.88
18.31
16.39
18.53
18.53
17.46
17.85
18.8
Operating Margin (%)
7,632
7,548
8,021
8,811
11,395
12,953
12,110
12,381
14,643
15,842
23,955
25,416
27,431
31,807
35,888
39,033
18,813
Depreciation Expense
9,764
11,411
12,007
14,165
20,573
26,638
39,278
40,635
39,221
41,224
34,882
31,904
44,092
45,784
49,639
53,669
27,452
Net Income, GAAP
36.2
35.55
36.54
37.3
38.5
41.75
32.05
17.35
32.76
28.97
29.57
31.1
31.51
33.46
33.28
32.37
33.13
Effective Tax Rate (%)
8.4
9.15
8.91
9.73
11.15
12.03
15.55
16.26
13.91
14.05
11.55
10.46
12.12
11.15
10.76
10.55
11.03
Profit Margin (%)
41,283
48,939
55,432
68,987
71,813
72,893
90,362
106,366
114,156
124,176
121,559
140,926
173,010
184,389
225,375
241,995
235,106
Working Capital
808
562
261
246
356
199
733
- -
- -
- -
16,935
16,178
15,840
15,442
46,680
55,485
47,314
LT Debt
87,136
94,232
102,502
119,153
146,250
157,973
182,801
210,252
241,443
265,182
278,347
306,089
349,053
388,356
432,897
464,534
441,720
Total Equity
11
12.4
11.94
11.93
14.5
16.01
23.04
21.17
17.5
16.7
13.45
10.75
12.85
12.5
11.61
11.78
6.46
Return on Invested Capital (%)
12.73
14.08
14.22
15.91
20.03
21.13
25.2
22.1
18.42
17.22
12.92
10.66
13.64
13.12
12.64
12.2
6.69
Return on Capital (%)
13.67
14.37
14.36
15.97
20.18
21.26
25.25
21.93
18.36
17.13
13.21
11.31
14.46
13.7
13.61
13.44
7.21
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
8,659
- -
8,362
LT Borrowings
28,600
- -
31,569
LT Finance Leases
18,080
- -
15,745
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
623
- -
623
Market Capitalization
5,249,638
1,477,758
1,820,067

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
343,459
- -
342,509
Cash, Cash Equivalents & STI
76,817
- -
93,003
Accounts Receivable, Net
157,067
- -
137,599
Inventories
79,123
- -
82,516
Total Current Liabilities
118,084
- -
107,403
Payables & Accruals
- -
- -
- -
ST Debt
8,659
- -
8,362
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.44%
10.81%
7.31%
Free Cash Flow
21.3%
26.43%
179.18%
Net Income, GAAP
8.72%
10.01%
8.12%
Sales/Revenue/Turnover
8.86%
11.15%
10.21%
Total Cash Common Dividend
10.99%
3.81%
2.86%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
95,351
117,347
113,826
134,985
461,510
2025
- -
- -
- -
- -
508,643
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13.73
21.6
19.62
- -
79.27
2025
- -
- -
- -
- -
86.07
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
14
- -
14.05
- -
28.07
2025
- -
- -
- -
- -
29
2026
- -
- -
- -
- -
- -
Similar Companies
Tarsons Products Limited (TARSONS.NS)
Apria, Inc. (APR)
Elekta AB (publ) (0O5H.IL)
GlucoTrack, Inc. (IGAP)
The Cooper Companies, Inc. (0I3I.L)
SEED Co.,Ltd. (7743.T)
Business
Sysmex Corporation Sysmex Corporation develops, manufactures and sells diagnostic instruments, reagents and related software for in vitro diagnostics; its core offerings span hematology analyzers such as the XN-Series and XE-Series, urinalysis systems including the UN-Series, hemostasis products, immunochemistry reagents, clinical chemistry analyzers and informatics solutions like Sysmex WAM decision support software; the company also provides flow cytometry and life science instruments to hospitals, laboratories, research institutes and medical institutions worldwide. Founded in 1968 and headquartered at 1-5-1 Wakinohama-kaigandori, Chuo-ku, Kobe, Japan, Sysmex Corporation operates in more than 190 countries across Asia, North America, Europe, Latin America and other regions, with 76 subsidiaries supporting its global reach. In September 2025, Sysmex Corporation entered a share transfer agreement to acquire JEOL Ltd.'s clinical chemistry testing business, including the BioMajesty series analyzers, establishing a wholly owned subsidiary by April 2026 to expand its portfolio and accelerate global growth; earlier in 2025, Sysmex America announced plans for a new reagent manufacturing and distribution center in São José dos Pinhais, Brazil, to enhance operational efficiency and serve expanding Latin American markets; the company also deepened its strategic alliance with CellaVision AB in 2024 for next-generation cell morphology analyzers and formed a joint venture with JCR Pharmaceuticals for regenerative medicine and cell therapy development.